Gastrointestinal Cancer News

The FDA granted priority review to a supplemental biologics license application that seeks approval of the HPV 9-valent vaccine, recombinant, for use among women and men aged 27 to 45 years for the prevention of HPV-related cancers.

To make colorectal screening more affordable and available, AMA delegates endorsed an advocacy effort at their annual meeting today that supports Medicare coverage for colorectal cancer screenings that are in line with Affordable Care Act-compliant plans.

CHICAGO — PET scan response after induction chemotherapy may be a useful prognostic and predictive tool for esophageal cancer, according to findings presented at ASCO Annual Meeting.

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

WASHINGTON — In this exclusive industry perspective from Digestive Disease Week 2018, Kevin Conroy, CEO of Exact Sciences, discusses the company’s noninvasive Cologuard colon cancer test and recent data on a new noninvasive test for the detection of liver cancer.

A broad spectrum of foods and beverages produced an equally diverse range of health benefits, according to findings presented at Nutrition 2018, the first-ever flagship meeting of the American Society for Nutrition.

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, John B. Kisiel, MD, a gastroenterologist from the Mayo Clinic in Rochester, Minn., shares results of a study in which plasma assay of methylated DNA markers detected hepatocellular carcinoma across all stages.

Cancer increased patients’ risk for subsequently developing diabetes, according to results of a cohort study conducted in South Korea.

The nation’s 70 NCI-designated cancer centers issued a joint statement today calling for increased gender-neutral HPV vaccination and evidenced-based screening in hopes of eliminating cancers caused by the virus.

CHICAGO — Preoperative chemotherapy with radiation demonstrated a significant survival benefit compared with surgery alone among patients with borderline resectable pancreatic cancer, according to preliminary results of the phase 3 randomized controlled PREOPANC trial presented at the ASCO Annual Meeting.